Treatment options for hypertension in high-risk patients

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 137-141

  Tsai, Wei Chuan ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antihypertensive agent; High risk; Hypertension

Indexed keywords

CARDIOVASCULAR AGENT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79960942479     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S11235     Document Type: Review

References (25)

1. Chiang CE, Wang TD, Li YH, et al. 2010 Guideline of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109:740-773.
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903-1913.
3. Kannel WB. Risk stratification in hypertension: New insight from the Framingham Study. Am J Hypertens. 2000;13(1 Pt 2):S3-S10.
4. Deedwania P. Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. J Clin Hypertens. 2007; 9:883-888.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;42: 1206-1252.
6. Kannel WB. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther. 1997;11 Suppl 1:199-212.
7. Kempler P. Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors. Diabetes Res Clin Pract. 2005;68 Suppl 1: S43-S47.
8. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
9. Chobanian AV, Bakris JL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289: 2560-2571.
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guideline for the management of arterial hypertension. Blood Press. 2007;16: 135-132.
11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-concerting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342: 145-153.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003.
13. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcome Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomized controlled trial. Lancet. 2005;366:895-906.
14. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): A randomized controlled trial. Lancet. 2007;370:829-840.
15. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358: 1547-1559.
16. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. Lancet. 2008;372:1174-1183.
17. The ACCOMPLISH Trial Investigators. Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
18. Staessen JA, Richart T, Wang Z, et al. Implications of recently published trials of blood pressure lowering drugs in hypertensive or high-risk patients. Hypertension. 2010;55:819-831.
19. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27: 923-934.
20. The ACCORD Study Investigators. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1575-1585.
21. The VALUE Trial Investigators. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet. 2004;363: 2022-2031.
22. Gaddam KK, Oparil S. Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens. 2008;17:484-490.
23. Cagnoni F, Njwe CAN, Zaninelli A, et al. Blocking the RAAS at different levels: An update on the use of the direct renin inhibitors alone or in combination. Vasc Health Risk Manage. 2010;6:549-559.
24. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res. 2010; 33:279-287.
25. Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomized, parallel-group trial. Lancet. 2011;377:312-320.